Compare AbbVie Inc (ABBV) vs Victoria's Secret & Co (VSXY) Price & Performance

AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).

Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.

Victoria's Secret (VSXY) trades at $78.25, up 2.01% with strong momentum as the stock benefits from international expansion and improved fundamentals. The company has beaten earnings expectations for three consecutive quarters, with Q1 2026 EPS of $0.60 surpassing the $0.32 estimate. Technical indicators show a neutral overall signal while the stock trades near pivot point resistance at $78. Analyst consensus remains bullish with a $88.56 price target representing 13% upside potential.

The outlook appears positive with international sales growing 44.9% in Q1 2026 and margin recovery underway, though risks include competitive pressures and execution challenges in global expansion. With improving cash flow projections and shareholder support for management's strategy, VSXY offers growth potential but requires monitoring of consumer spending trends and inventory management.